Cost-effectiveness analysis of systemic therapy for non-small cell lung cancer based on real-world data

Cost-effectiveness analysis of systemic therapy for non-small cell lung cancer based on real-world data - Cost-effectiveness analysis of systemic therapy for non-small cell lung cancer based on real-world data

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000052124

Enrollment

100

Registered

2023-09-05

Start date

2023-09-19

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

non-small cell lung cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The study will include patients who meet the following criteria: Patients diagnosed with unresectable, advanced recurrent non-small cell lung cancer. Patients receiving anticancer drug treatment for unresectable, advanced recurrent non-small cell lung cancer. Patients with ECOG Performance Status (PS) of 0 or 1. Patients aged 20 years or older at the time of obtaining consent. Patients who have provided consent to participate in this trial. The definition of unresectable, advanced recurrent cancer is as follows: Stage III with inoperable lesions due to the impossibility of curative radiotherapy. Stage IV. Postoperative recurrence. Recurrence after radiation monotherapy.

Exclusion criteria

Exclusion criteria: Patients with the following driver gene mutations or translocations will be included: EGFR gene mutation ALK fusion gene ROS1 fusion gene BRAF gene mutation MET gene mutation RET fusion gene NTRK fusion gene In the future, if new primary standard treatments are identified for additional driver gene mutations or translocations, patients with those newly identified driver gene mutations or translocations will also be excluded from the study.

Design outcomes

Primary

Measure	Time frame
From the initiation of anticancer drug treatment following fulfillment of inclusion criteria until the date of death, the incremental cost-effectiveness ratios (ICERs) for the four groups, namely B to E, relative to the base case A, are as follows: A. Cytotoxic anticancer agent B. Platinum combination therapy + PD-1/PD-L1 inhibitor C. Platinum combination therapy + PD-1 inhibitor + CTLA-4 inhibitor D. PD-1 inhibitor + CTLA-4 inhibitor E. PD-1/PD-L1 inhibitor We will evaluate and compare the ICERAB, ICERAC, ICERAD, and ICERAE to assess the cost-effectiveness of these different therapeutic approaches for the specified patient population.	—

Measure

Time frame

From the initiation of anticancer drug treatment following fulfillment of inclusion criteria until the date of death, the incremental cost-effectiveness ratios (ICERs) for the four groups, namely B to E, relative to the base case A, are as follows: A. Cytotoxic anticancer agent B. Platinum combination therapy + PD-1/PD-L1 inhibitor C. Platinum combination therapy + PD-1 inhibitor + CTLA-4 inhibitor D. PD-1 inhibitor + CTLA-4 inhibitor E. PD-1/PD-L1 inhibitor We will evaluate and compare the ICERAB, ICERAC, ICERAD, and ICERAE to assess the cost-effectiveness of these different therapeutic approaches for the specified patient population.

—

Countries

Japan

Contacts

Public ContactTakenori Ichimura

Showa University School of Pharmacy Department of Hospital Pharmaceutics

ichimura@cmed.showa-u.ac.jp03-3784-8000

Outcome results